Latest news with #IsabelPreeshagul
Medscape
2 days ago
- Health
- Medscape
ASCO 2025: Clinical Impact of New Data in Advanced NSCLC
Isabel Preeshagul, DO, comments on treatment updates in advanced non-small cell lung cancer shared at ASCO 2025, emphasizing their impact on patients. The KRYSTAL-7 study showed that adagrasib combined with pembrolizumab achieved a 43% response rate in KRAS G12C-mutant patients, especially those with PD-L1 over 50%, though liver toxicity was a key concern. The REZILIENT1 study highlighted zipalertinib's activity in EGFR exon 20 insertion–positive patients, with encouraging CNS responses and manageable side effects like paronychia. Lastly, the COCOON study showed that a proactive dermatologic regimen significantly reduced skin toxicities from amivantamab, though practical challenges remain in balancing effectiveness with patient burden.
Medscape
09-06-2025
- Health
- Medscape
ASCO 2025: Key Highlights in Advanced Lung Cancer
Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response. In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.
Medscape
19-05-2025
- Health
- Medscape
ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC
Isabel Preeshagul, DO, is eagerly anticipating ASCO 2025, especially the progress being made in advanced NSCLC within the targeted therapy space. Promising developments include treatments for KRAS G12C alterations, particularly the LOXO-RAS-20001 phase 1/2 study combining olomorasib with immunotherapy, and for EGFR exon 20 insertions, where zipalertinib is showing potential after frontline therapy. In the HER2 space, new small-molecule tyrosine kinase inhibitors such as zongertinib, BAY 2927088, and NVL-330 are generating excitement, especially regarding their central nervous system penetration. Beyond targeted therapies, there's strong interest in antibody-drug conjugates, notably the TROPION-Lung02 study evaluating datopotamab deruxtecan in combination with pembrolizumab and chemotherapy.
